Graduate in Science from a recognized university with 3 years of work experience from a recognized institution OR master’s degree in Science OR Pharm.D (Doctor of Pharmacy) from a recognized institution.
Master of Pharmacy in Pharmaceutics with First Division and GPAT Qualified. Prior experience in handling machines like Spray Dryer, Texture Analyzer, Rheometer and HPLC.
Graduate in Science from a recognized university with 3 years of work experience from a recognized institution OR masters degree in Science OR Pharm.D (Doctor of Pharmacy) from a recognized institution.
Candidates having Ph.D. degree in Life Sciences / Biotechnology / Molecular Biology or a related field with at least three years of research experience in science and technology organizations / academic institutions.
First Class Post Graduate Degree in Life Science, Microbiology or Biotechnology or Molecular & Human Genetics, including the integrated PG degrees from a recognized Institution
PhD in Chemistry from a recognized institute. Research Associate-I under the project Odisha Hydrogen Valley Innovation Cluster in the School of Chemical Sciences, NISER, Bhubaneswar funded by DST, Govt of India
You are currently pursuing a masters degree or are currently in the third or fourth year of a four-year bachelors degree, the third year of a three-year bachelors degree, or the third to fifth year of an integrated/ dual degree in any science subject, and will remain so for the duration of the fellowship.
PhD with a minimum of 55% in post-graduation (M.Sc / M. Pharm / M.Tech. degree in Biotechnology or allied discipline), Experience in Immunology, Cancer model, cell culture etc., Strong expertise and publication in the domain of immunology and cancer biology, Experience in pharmaco-immunology and preclinical models.
Post Graduate Degree, including the integrated PG degrees, with five years’ post qualification experience or PhD + two years post qualification experience.
Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.
Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease
Master’s degree in any field preferably in science, with 6 years of post- qualification experience in clinical data management/ clinical research/operations/ MIS/ data analysis/ IT/ computer science/ healthcare field